1

# SUPPLEMENTARY METHODS

# Human ASXL1 Deficiency Causes Epigenetic Dysfunction, Combined Immunodeficiency and EBV–Associated Hodgkin Lymphoma

3 4 5

2

6 Maggie P Fu<sup>1\*</sup>, Mehul Sharma<sup>2\*</sup>, Sarah M Merrill<sup>3</sup>, Pariya Yousefi<sup>2</sup>, Ryan Tan<sup>2</sup>, Bhavi P

7 Modi<sup>2</sup>, Kate Del Bel<sup>2</sup>, Rebecca J Deyell<sup>4</sup>, Jacob Rozmus<sup>4</sup>, Wingfield Rehmus<sup>2,5</sup>, Kyla J

Hildebrand<sup>2</sup>, Elliot James<sup>2</sup>, Géraldine Blanchard-Rohner<sup>2,6</sup>, Susan Lin<sup>2</sup>, Kevin E
 Shopsowitz<sup>2,7</sup>, Audi Setiadi<sup>7</sup>, Jefferson Terry<sup>7</sup>, Anna F Lee<sup>7</sup>, Britt I Drögemöller<sup>8,9</sup>,

9 Shopsowitz<sup>2,7</sup>, Audi Setiadi<sup>7</sup>, Jefferson Terry<sup>7</sup>, Anna F Lee<sup>7</sup>, Britt I Drögemöller<sup>8,9</sup>,
 10 Allison Matthews<sup>1,10</sup>, Maja Tarailo-Graovac<sup>1,11</sup>, Laura Sauvé<sup>2,12</sup>, Hana Mitchell<sup>2</sup>, Julie S

11 Prendiville<sup>2,5</sup>, Julie L MacIsaac<sup>1,13</sup>, Kristy Dever<sup>1,13</sup>, David T S Lin<sup>1</sup>, Mandy Meijer<sup>1,13</sup>,

12 Colin J D Ross<sup>9</sup>, Simon R M Dobson<sup>2,12</sup>, Suzanne M Vercauteren<sup>7</sup>, Wyeth W

13 Wasserman<sup>1</sup>, Clara D M van Karnebeek<sup>2,14,15</sup>, Margaret L McKinnon<sup>2,16</sup>, Michael S

- 14 Kobor<sup>1,13#</sup>, Stuart E Turvey<sup>2#</sup>, Catherine M Biggs<sup>2#</sup>
- 15
- <sup>1</sup>British Columbia Children's Hospital, Centre for Molecular Medicine and Therapeutics,
- 17 Department of Medical Genetics, University of British Columbia, Vancouver, BC, 18 Canada.
- <sup>2</sup>Department of Pediatrics, British Columbia Children's Hospital, The University of British
   Columbia, Vancouver, BC, Canada.
- <sup>3</sup>Department of Psychiatry and Human Behavior, The Warren Alpert Medical School at
- 22 Brown University, Providence, RI, USA.

<sup>4</sup>Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, British

24 Columbia Children's Hospital, University of British Columbia, Vancouver, BC, Canada.

<sup>5</sup>Divisions of Pediatric Dermatology, Department of Pediatrics, British Columbia

26 Children's Hospital, University of British Columbia, Vancouver, BC, Canada.

- <sup>6</sup>Unit of Immunology and Vaccinology, Division of General Pediatrics, Dept. of Woman,
- 28 Child, and Adolescent Medicine, Geneva University Hospitals and Faculty of Medicine,
- 29 University of Geneva, Geneva, Switzerland.
- <sup>7</sup>Department of Pathology and Laboratory Medicine, University of British Columbia,
- 31 Vancouver, BC, Canada.
- <sup>8</sup>Department of Biochemistry and Medical Genetics, Rady Faculty of Health Sciences,
- 33 University of Manitoba, Winnipeg, MB, Canada.
- <sup>9</sup>Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC,
- 35 Canada.
- <sup>10</sup>Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada.
- <sup>11</sup>Alberta Children's Hospital Research Institute, Department of Biochemistry and
- 38 Molecular Biology and Department of Medical Genetics, Cumming School of Medicine,
- 39 University of Calgary, Calgary, Alberta, Canada.
- 40 <sup>12</sup>Pediatric Infectious Diseases, Department of Pediatrics, British Columbia Children's
- 41 Hospital, University of British Columbia, Vancouver, BC, Canada.
- <sup>13</sup>Edwin S.H. Leong Healthy Aging Program, University of British Columbia, Vancouver,
   Canada.
- <sup>14</sup>Departments of Pediatrics and Human Genetics, Emma Center for Personalized
- 45 Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands.

2

- <sup>15</sup>Centre for Molecular Medicine and Therapeutics, BC Children's Hospital Research 46
- 47 Institute, Vancouver, Canada.

**Correspondence to:** 

<sup>16</sup>Department of Medical Genetics, University of British Columbia, Vancouver, Canada. 48

Catherine M. Biggs, MD, MSc

Phone: 604-875-2118 ext 2 Email: cbiggs@bcchr.ca

Vancouver, BC, V5Z 4H4, Canada

BC Children's Hospital,

4480 Oak St,

- 49 50
- \*These authors contributed equally. 51
- <sup>#</sup>These authors contributed equally. 52
- 53
- 54
- 55
- 56

57

58

```
59
```

### 62 SUPPLEMENTARY METHODS

#### 63 Sanger sequencing

Briefly, standard sequencing of genomic DNA from all individuals of the family was
performed to confirm genotype segregation with the disease in the family using the
following primers: Var1: Forward 5'-GAATGACTGCCTTGCTTTAAGA-3', Reverse 5'AAAGGTTAGTCCCTAGTGCC-3'; Var2: Forward 5'-TGCCAGATAGCTGTGAAACA-3',
Reverse 5'-CACATTTGGAGATGAGAAACGA-3'.

69

#### 70 Identification of candidate variant

71 Based on family history and pedigree, once a candidate variant list was generated by

72 the pipeline, variants identified through the de novo, autosomal recessive, and

73 compound heterozygous inheritance models were first assessed. All high-impact,

74 putative loss-of-function (LoF) variants were reviewed. Next, the candidate variant list

vas screened for variants in genes associated with inborn errors of immunity (IEI),

respecially those previously linked with vaccine-strain rubella-associated granulomas.

77 Genes associated with DNA repair deficiency disorders as well as telomeropathies were

78 also investigated.

In addition, a phenotype-driven approach was also employed to identify relevant

80 variants in genes that may be associated with clinical features (using associated MeSH

81 and HPO terms) presented by the proband, such as multiple skin lesions, necrotizing

granulmatous inflammation (postvaccine rubella strain identification), idiopathic chronic

83 macrocytosis, low T-cell count, high B-cell count, mild megablastoid changes, mild

84 dysplastic features, infections, pneumonia, failure to thrive, learning disability, and

85 subtle dysmorphic features.

86

# 87 Generation and maintenance of primary patient T-cells and fibroblasts

T-cells were treated with exogenous IL-2 (10 U/mL) and ImmunoCult<sup>™</sup> Human

89 CD3/CD28 T Cell Activator (Cat # 10971; Stemcell, Vancouver, BC, Canada) for 12

- 90 days and maintained at a concentration of 10<sup>6</sup> cells/mL every 2 days. After 12 days,
- 91 exogenous IL-2 concentration was increased to 1000 U/mL.
- 92 To grow fibroblasts, patient skin was incubated with complete DMEM composed of 10%
- 93 heat-inactivated FBS (Gibco-BRL Life Technologies, Grand Island, NY, USA; Life
- 94 Technologies, Gaithersburg, MD, USA), 2mM L-glutamine (HyClone, Thermo Fisher
- 95 Scientific, Waltham, MA, USA), 1mM sodium pyruvate (Gibco-BRL Life Technologies),
- 96 and 1× Antibiotic-Antimycotic (Gibco-BRL Life Technologies, Thermo Fisher) for 3
- 97 weeks at 37°C or until a confluent monolayer of fibroblasts had formed. Primary
- 98 fibroblasts were then lifted and frozen at  $-80^{\circ}$ C for future assays.
- 99

### 100 Stable expression of ASXL1 using a lentivirus vector

101 To generate lentivirus vectors, wild-type ASXL1 (NM\_015338) plasmid (Cat#:

- 102 RG219354; OriGene Technologies, Rockville, MD, USA) was cloned into a GFP-tagged
- Lenti vector (Cat#: PS100071; OriGene Technologies) using Ascl (Cat#: R0558L) and
- 104 *Mlul-HF* (Cat#: R3198L) (both from New England Biolabs, Ipswich, MA, USA). The
- plasmid was packaged using third-generation packaging plasmids and transfected into
   HEK293T cells. Culture medium was collected, centrifuged, filtered, concentrated, and
- stored at -80°C until use. Expanded T-cells were infected with lentiviral particles and
   expanded in complete RPMI-1640 (GE Healthcare, Chicago, IL, USA) supplemented
- 109 110

with 10% FBS for 9 days.

# 111 Intracellular flow cytometry in PBMCs, expanded T-cells, and primary fibroblasts

112 Expanded T-cells were first washed and stained with CD4 BUV563 (Clone: SK3, Cat#

- 113 612912; BD Biosciences, Franklin Lakes, NJ, USA), CD8 BUV395 (Clone: RPA-T8,
- 114 Cat# 563796; BD Biosciences), and Fixable Viability Stain 780 (Cat#565388; BD
- 115 Biosciences) for 15 minutes. Cells were then fixed (fibroblasts were lifted, spun, and
- 116 fixed) using BD Cytofix (Cat# 554655; BD Biosciences) for 20 minutes at room
- temperature and permeabilized using Perm III for 30 minutes on ice (Cat# 558050; BD
- Biosciences). The cells were then stained with either primary antibody for ASXL1 (Cat#
- 119 MA5-36238; Thermo Fisher Scientific) or mouse IgG1 isotype control for 1 hour at room

120 temperature in 1× Perm/Wash (Cat# 554723; BD Biosciences). Intracellular staining

- 121 was performed separately for H2AK119ub (Cat# 8240S; Cell Signaling Technology,
- 122 Danvers, MA, USA) in expanded T-cells. Subsequently, the cells were washed and
- stained with goat anti-mouse secondary antibody (Alexa Fluor™ 405, Cat#: A-31553;
- 124 Thermo Fisher Scientific) for 30 minutes at room temperature. ASXL1 expression was
- then measured using a BD FACSymphony flow cytometer (BD Biosciences) and
- 126 analyzed using FlowJo software (BD Biosciences).
- 127 Detection of pSTAT5 was performed similar to the protocol outlined above in expanded
- 128 T-cells and in primary patient peripheral blood mononuclear cells (PBMCs). After
- 129 permeabilization, cells were stained with mouse anti-human pSTAT5 (pY694) PE-Cy7
- 130 (Cat# 560117; BD Biosciences). The following antibodies were used for extracellular
- 131 staining of PBMCs: CD3 FITC (Clone: UCHT1, Cat# 555332; BD Biosciences), CD4
- 132 BUV563 (Clone: SK3, Cat# 612912; BD Biosciences), CD8 BUV395 (Clone: RPA-T8,
- 133 Cat# 563796; BD Biosciences), CD27 BV605 (Clone: L128, Cat#: 562655; BD
- 134 Biosciences), CD45RA BV421 (Clone: HI100, Cat#: 562885; BD Biosciences).
- 135

# 136 Clinical-grade flow cytometry

Patient clinical immunophenotyping was carried out on whole blood at an accredited 137 138 clinical flow cytometry laboratory according to standard protocols. Briefly, whole blood was collected and stained using dried antibody reagents (DURAClone tubes; Beckman 139 Coulter, Brea, CA, USA) according to the manufacturer's recommendations. Panels 140 focused on the analysis of T-cell subsets (DURAClone IM T Cell Subsets, Cat#: 141 142 B53328; Beckman Coulter) and B-cell subsets (DURAClone IM B Cell, Cat#: B53318; Beckman Coulter). Samples used for the B-cell subsets were washed three times prior 143 to staining. Aliquots of 100 µL of fresh blood were added to the dried reagent tubes and 144 incubated in the dark at room temperature for 15 minutes prior to lysis with ImmunoPrep 145 Reagent System (Beckman Coulter). Samples were then fixed with 1.0 mL of 1% 146 paraformaldehyde prior to flow cytometry. All flow data were acquired on a Navios flow 147 148 cytometer and then analyzed using Kaluza software (Beckman Coulter). 149

### 150 **DNA extraction for DNA methylation array analysis**

151 Whole blood was collected in Vacutainer® CPT™ Cell Preparation Tubes (Becton 152 Dickinson, Franklin Lakes, NJ, USA). PBMCs were then isolated by standard Ficoll-Plaque (GE Healthcare) density centrifugation. Buccal swabs were collected with 153 Isohelix Buccal Swabs (Cell Projects Ltd., Kent, UK) and Oragene DNA sample 154 collection kits (DNA Genotek, Kanata, ON, Canada), respectively. Genomic DNA was 155 extracted from whole blood, PBMCs, and expanded T-cells with DNeasy kits (Qiagen, 156 157 Germantown, MD, USA). Buccal DNA was extracted with Isohelix Buccal DNA Isolation 158 kits (Cell Projects Ltd.). Extracted DNA (750 ng) was subjected to bisulfite conversion 159 with an EZ-96 DNA Methylation kit (Zymo Research, Irvine, CA, USA), and aliquots of 160 ng were assayed with Infinium HumanMethylationEPIC BeadChip arrays (Illumina, 160 161 San Diego, CA, USA).

162

### 163 Sample selection for pediatric population reference set

164 We gathered all cohorts in whole blood, PBMCs, and dried blood spots (DBSs), and 165 excluded cord blood samples. To ensure consistent data preprocessing and 166 minimization of batch effects, we used only cohorts for which raw IDAT files were available in the database. The methylation data and metadata were then compiled 167 manually. Missing metadata were curated from the GEO data set publications and 168 169 included variables such as age, sex, tissue, ethnicity, and disease status. For disease 170 status, we used the designation of "healthy control" (HC) for samples collected from individuals without persistent severe health conditions, as described in the cohort 171 172 metadata and the associated publication. Only cohorts that included age information and had samples in the pediatric age range were retained. After guality control (QC). 173 174 outlier removal, age matching (6–18 years), and selection for HCs, 725 buccal samples, 175 452 WB samples, 285 PBMC samples remained.

176

## 177 Epigenetic age analysis

The DNAmAge function in the methylclock package was used to estimate all DNAm
ages in parallel.<sup>1</sup> Epigenetic age acceleration (EAA) was calculated by fitting regression

- of epigenetic age (EA) to chronological age (CA) and extracting the residual,
- 181 representing the component of EA that could not be explained linearly by the CA
- process, whereas epigenetic age difference (EAD) was defined as the difference
- 183 between EA and CA.
- 184

## 185 Normalization, QC, and imputation of DNA methylation data

- 186 For the analysis of primary tissues, the HC cohorts and patient samples were
- 187 preprocessed together. All subsequent analyses were performed in R version 4.0.3 (R
- 188 Foundation for Statistical Computing, Vienna, Austria). The IDAT files were normalized
- 189 with the *preprocessFunnorm* function in the minfi package, which included two types
- 190 of normalization: Noob (normalized out-of-band) normalization and functional
- 191 normalization.<sup>2,3</sup> The two normalization steps utilized the readings from control and out-
- 192 of-band probes to adjust for dye bias from the two-color channels and probe-type bias
- 193 from Type I and Type II probes on the arrays, respectively. Samples from the 450k and
- 194 EPIC microarrays were normalized separately, and then combined by subsetting to the 195 shared probes.
- 196 QC was performed at both sample and probe levels. Samples with bisulfite conversion
- 197 rate < 75 or average detection *P*-value > .01 were removed. Three other outlier
- 198 detection methods—*detectOutlier* from lumi,<sup>4</sup> *outlyx* from wateRmelon,<sup>5</sup> and Z-test on
- the first principal component (PC)—were implemented to identify outliers with distinct
- 200 methylation patterns. Furthermore, sex prediction was performed with the *getSex*
- removed. Finally, probes in which > 5% of samples had bead count < 3 or an average
- 203 detection *P*-value > .05 were filtered out.
- After QC, the missing values were imputed in a probe-wise manner based on the DNAm
- 205 patterns of other probes with the lowest Euclidean distance. The method was
- implemented with the *imputeKNN* function in the impute package, where k = 10.

#### 208 Cell type proportion prediction

Cell type proportion of whole blood and PBMC DNAm data were estimated from the
imputed data with the Houseman reference-based prediction method,<sup>6</sup> as implemented
using the *estimateCellCounts2* function from the FlowSorted.Blood.EPIC package
with the FlowSorted.BloodExtended.EPIC reference.<sup>7</sup> In buccal swabs, cell type
proportion was predicted with the *hepidish* function in the EpiDISH package<sup>8</sup>. We
compared the estimated proportion of each cell type between the patient and HCs using
the one-sample *t* test.

216

#### 217 Correcting for variances associated with intersample cellular heterogeneity

Given that the patient shows unique cell type proportions distinct from the HC, it is 218 219 essential to adjust for cell type-associated DNAm variation to prevent confounding with 220 the disease-associated DNAm signature. In the primary tissues, this was accounted for with a regression model. To overcome the compositional nature of cell type proportion 221 data, we first transformed the proportion into an isometric log ratio followed by principal 222 223 component analysis (PCA) to extract components that capture the variabilities corresponding to cell type differences, yet are not bounded or correlated. We then fitted 224 a regression model of the DNAm beta value as a function of the cell type PCs<sup>9</sup> and 225 extracted the residuals as the cell type-adjusted DNAm values. For the analysis in T-226 227 cells, we accounted for the CD8 proportion directly as a covariate in our EWAS.

228

#### 229 Batch correction

230 Given that we only included samples for which raw IDAT files were available, we also 231 had access to the chip ID and position at which each sample was run. We identified three known sources of batch effect, ie, the array platform (450k or EPIC), chip ID, and 232 chip row. Therefore, we adjusted the data for these three known batch effects with the 233 *ComBat* function in the sva package,<sup>10</sup> which uses an empirical Bayesian framework to 234 235 estimate the batch effect on samples across probes and account for them with a regression model. Each cohort can also be considered as a batch, but that is often 236 confounded with different tissues, disease status, and age range, so we did not include 237

cohort as a known batch variable. We confirmed that the batch effect of the three

- variables were removed with PCA. Platform ID, chip ID, and chip row were originally
- strongly correlated with PC1 through PC5 on Pearson's correlation test (multiple test
- adjusted *P* < .001), and most of the effects were removed by *ComBat*. For the T-cell
- 242 DNAm data, we accounted for batch in the limma regression model, as too few batches
- were present, and we did not detect a strong batch effect within each time point.
- 244

# 245 Differential DNAm analysis of expanded T-cells

The expanded T-cells for the DNAm arrays were collected over 3 days to capture some 246 247 biological and technical variability. In the linear regression model, we accounted for concomitant variables in our analysis, including sex, age, and technical batch, to 248 specifically isolate the effect of patient ASXL1 genotype. We identified 276 769 249 differentially methylated sites (DMs) with a statistical cutoff with  $P_{adj} \leq .05$  and effect size 250 (ES) cutoff with delta-beta > 0.1. The same regression model comparing rescue vs. 251 control yielded 208,692 DMs passing the statistical and ES thresholds. We then 252 253 included flow-derived CD8<sup>+</sup> proportion with other concomitant variables in the model to account for cellular heterogeneity. With the new model, we no longer observed any DMs 254 255 passing the statistical threshold of  $P_{adj} < .05$ , showing that ASXL1 variants led to an 256 imbalance in CD4<sup>+</sup> and CD8<sup>+</sup> T-cell proportions, and that ASXL1 has a strong cell population-specific effect on DNAm pattern. We relaxed the statistical threshold to  $P_{adj}$  < 257 258 .2 and detected 141,113 DMs. Downstream analysis are performed with this model and 259 detection threshold.

260

# 261 Enrichment analysis for differential DNA methylation

Overrepresentation analyses were conducted using the *gometh* function in the missMethyl package to identify enriched ChromHMM chromatin states. The ChromHMM states were exported from the Roadmap Epigenomics database and overlapped with the Illumina annotation file for the EPIC arrays.<sup>11</sup> The method accounts for the background probes on the DNAm arrays to minimize coverage biases. The probes were annotated to the corresponding genes and the enriched pathways with multiple test-adjusted P < .05 were identified.

#### 269 Supplementary Clinical Data

#### 270 Presentation and treatment of EBV-associated Hodgkin lymphoma

271 Between 10 to 15 years of age the patient presented with a three-month history of epistaxis and gum bleeding. Mildly reduced platelets with elevated mean platelet 272 273 volume, suggestive of peripheral destruction, prompted an abdominal ultrasound which 274 identified hepatosplenomegaly. A chest CT demonstrated diffuse intrathoracic 275 lymphadenopathy and baseline positron emission tomography (PET)-CT revealed <sup>18</sup>Ffluorodeoxyglucose (FDG)-avid disease above and below the diaphragm, pulmonary 276 nodules, hepatic and splenic lesions with innumerable marrow deposits. An axillary 277 lymph node biopsy confirmed the diagnosis of stage IVA classical Hodgkin lymphoma. 278 mixed cellularity subtype with prominent granulomatous inflammation (Supp Fig 1D). 279 280 She had an associated EBV viremia (EBV viral load 15,529 copies/ml) and immunohistochemistry of Reed-Sternberg cells from her diagnostic lymph node biopsy 281 were positive for EBV-encoded RNA (EBER). Bone marrow aspirate and biopsy showed 282 numerous lymphohistiocytic aggregates, in addition to mild megakaryocytic atypia and 283 284 mild red blood cell macrocytosis.

285

She received 2 cycles of ABVD (doxorubicin [adriamycin], bleomycin, vinblastine and 286 dacarbazine) chemotherapy with a partial metabolic response (Deauville 4), and was 287 288 then switched to AVD with brentuximab-vedotin, the anti-CD30 antibody, for cycles 3 289 and 4 due to significant myelosuppression and slow early response. Repeat PET-CT 290 done after 4 cycles of chemotherapy showed progressive disease with 2 new FDG-avid 291 lesions (spleen and right humerus). The splenic lesion was biopsied and histology 292 remained in keeping with classical Hodgkin lymphoma. Following tumour board review, 293 she initiated immunotherapy with nivolumab, the anti-programmed cell death protein 1 294 (PD1) antibody. This was complicated by the development of autoimmune thyroiditis. which was treated with thyroxine. She completed 4 cycles of nivolumab after which 295 296 PET-CT re-evaluation was indeterminate with persistent FDG-avid lesions potentially 297 related to her chronic skin lesions and an intercurrent axillary seroma, but no definitive 298 disease progression. Six weeks following discontinuation of nivolumab, she began conditioning for a 9/10 matched unrelated donor hematopoietic stem cell transplant with 299

- 300 cyclophosphamide, fludarabine and 200cGy total body irradiation. She received
- 301 mycophenolate mofetil and tacrolimus prophylaxis for graft versus host disease (GVHD)
- 302 and developed grade 1 GVHD of upper gut and skin which was treated with
- 303 corticosteroids. She was discharged on day +34 with full donor chimerism, and remains
- 304 well now 6 months post-transplant with healing of her chronic skin lesions.

### 305 SUPPLEMENTARY REFERENCES

306

Pelegi-Siso D, de Prado P, Ronkainen J, Bustamante M, Gonzalez JR.
 methylclock: a Bioconductor package to estimate DNA methylation age. Bioinformatics
 2021;37:1759-60.

Fortin JP, Labbe A, Lemire M, et al. Functional normalization of 450k methylation
 array data improves replication in large cancer studies. Genome Biol 2014;15:503.

312 3. Fortin JP, Triche TJ, Jr., Hansen KD. Preprocessing, normalization and 313 integration of the Illumina HumanMethylationEPIC array with minfi. Bioinformatics 314 2017;33:558-60.

315 4. Du P, Kibbe WA, Lin SM. lumi: a pipeline for processing Illumina microarray.
316 Bioinformatics 2008;24:1547-8.

5. Pidsley R, CC YW, Volta M, Lunnon K, Mill J, Schalkwyk LC. A data-driven approach to preprocessing Illumina 450K methylation array data. BMC Genomics 2013;14:293.

- Houseman EA, Accomando WP, Koestler DC, et al. DNA methylation arrays as
   surrogate measures of cell mixture distribution. BMC Bioinformatics 2012;13:86.
- 322 7. Salas LA, Zhang Z, Koestler DC, et al. Enhanced cell deconvolution of peripheral
   323 blood using DNA methylation for high-resolution immune profiling. Nat Commun
   324 2022;13:761.
- 325 8. Zheng SC, Webster AP, Dong D, et al. A novel cell-type deconvolution algorithm
  326 reveals substantial contamination by immune cells in saliva, buccal and cervix.
  327 Epigenomics 2018;10:925-40.
- Jones MJ, Islam SA, Edgar RD, Kobor MS. Adjusting for cell type composition in
  DNA methylation data using a regression-based approach. Methods in Molecular
  Biology2017:99-106.
- 10. Leek JT, Johnson WE, Parker HS. The sva package for removing batch effects
  and other unwanted variation in high-throughput experiments. Bioinformatics
  2012;28:882-3.
- 11. Roadmap Epigenomics C, Kundaje A, Meuleman W, et al. Integrative analysis of
   111 reference human epigenomes. Nature 2015;518:317-30.

336 12. Gatev E, Gladish N, Mostafavi S, Kobor MS. CoMeBack: DNA methylation array
 337 data analysis for co-methylated regions. Bioinformatics 2020;36:2675-83.

Awamleh Z, Chater-Diehl E, Choufani S, et al. DNA methylation signature
associated with Bohring-Opitz syndrome: a new tool for functional classification of
variants in ASXL genes. Eur J Hum Genet 2022;30:695-702.

341

343

# 344 Supplementary Figure Legends:

345

346 Supp. Figure 1: A) White blood cell count assessment over time showed normal white blood cell count. B) Immunoglobulin assessment over time showed low IgG until 347 348 initiation of intravenous immunoglobulin (IVIG), low/normal IgM levels and low/normal IgA levels. C) Skin biopsy performed in childhood (0-10 years of age) from the left thigh. 349 350 Tissue section stained with hematoxylin and eosin showing subcutaneous necrotizing (\*) and nonnecrotizing granulomas (arrowhead). Specific staining for organisms was 351 352 negative (not shown). Scale bar: 200 µm. D) Micrograph of lymph node indicating juxtaposed granulomatous inflammation (\*) and classical Hodgkin lymphoma with 353 354 Reed-Sternberg cells (arrowheads). Scale bar: 200 µm.

355

**Supp. Fig. 2:** A) Predicted CADD score (v1.6) and allelic frequency of ASXL1 variants reported in the gnomAD database (v3). All missense (gray), stop-gained (navy blue), or frameshift (magenta) variants are plotted. Patient variants are indicated with a triangle.

360 Supp. Fig. 3: A) Volcano plot of differential DNAm pattern detected in buccal swabs with linear regression. Delta beta represented the effect size (regression coefficient) of 361 the patient status variable after accounting for sample age and sex. Magenta points 362 indicate DMs with increased DNAm in the patient, and turquoise points represent those 363 364 with decreased DNAm. The vertical gray line represents the delta-beta = 0.05, and the 365 horizontal line corresponds to  $P_{adj} = 0.05$ . B) Overlap of differentially methylated CpGs 366 identified in our whole blood analysis and those associated with Bohring-Opitz syndrome in a previous study<sup>13</sup>. C) CA and predicted PedBE EA in the patient and HCs. 367 HC samples are shown in light blue, while patient samples are shown in red. The black 368 369 line indicates the best fit line using linear regression of all the sample points. The gray area corresponds to the 95% confidence interval. D) Telomere length of patient 370 371 lymphocytes and granulocytes compared with the reference range in the HC population. 372

**Supp. Fig. 4:** A,B) Epigenetic age analysis in expanded T-cells, (n = 3 for patient and rescued samples). A) Difference in Horvath skin and blood epigenetic age and

chronological age. B) Difference in Hannum epigenetic age and chronological age. 0.05, \*\*P < .01, \*\*\*P < .001, one-way analysis of variance with Dunnett's multiple comparison test.

378

379 Supp. Fig. 5: Extended T-cell phenotyping of the index patient. pSTAT5 response in the A) memory CD4 T and B) memory CD8 T-cell subsets of patient and control 380 381 PBMCs after stimulation with 1, 10, or 100 U/mL IL-2. Patient (purple), family controls (orange), HCs (light blue). Two different time points of patient samples are presented 382 with different symbols (triangles and circles). C) Oxidative stress was detected in 383 expanded CD4<sup>+</sup> and CD8<sup>+</sup> T-cells of the patient and controls (family and HC) by flow 384 cytometry using CellROX Deep Red reagent. \*P < .05, \*\*P < .01, one-way analysis of 385 variance and Tukey's post hoc test. 386